Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 68, Issue 1, Pages 7-12Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2013.12.002
Keywords
MiR-137; KIT; SCLC; MDR
Funding
- National Natural Science Foundation of China [81071933]
Ask authors/readers for more resources
MiR-137 expression was examined in parental and drug-resistant cell lines, H446 and H446/CDDP, of small lung cancer (SCLC), and the results showed there was fewer miR-137 expressed in H446/CDDP cells followed by KIT expression emergence. In order to confirm physiological function of these abnormal expressions, H446 and H446/CDDP cells were transfected with miR-137 inhibitor and miR-137 mimics, respectively, after that, miR-137 and KIT expression in two cell lines and drug sensitivity of these cells were evaluated. Results indicated that sensitivity of H446 cells to cisplatin significantly decreased after transfected with miR-137 inhibitor, while miR-137 mimics transfection increased drug sensitivity of H446/CDDP cells and deregulated KIT expression. Our data provided combined evidence that miR-137 was closely related to MDR of SCLC, and interfering of miR-137 expression may attenuate drug resistant of H446/CDDP cells to cisplatin partially through KIT expression regulation. Besides, it has also been proved that KIT might be only one of the downstream molecules of miR-137 that related to SCLC MDR. (C) 2014 Published by Elsevier Masson SAS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available